Who is sponsoring NCT04913389?

NCT04913389 is sponsored by University of Zurich.

What drugs are being tested in NCT04913389?

Interventions in NCT04913389: Acetazolamide, Placebo.

What condition does NCT04913389 study?

NCT04913389 studies Chronic Obstructive Pulmonary Disease, Altitude Sickness, Altitude Hypoxia.

Is NCT04913389 still recruiting?

NCT04913389 is currently status unknown. Last updated 3 March 2023.

Last reviewed 2023-03-03 · How we verify

NCT04913389

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acetazolamide to Prevent Impending Altitude-illness in Patients With COPD

Status unknown Phase 3 Last updated 3 March 2023

What this trial tests

Phase 3 trial testing Acetazolamide in Chronic Obstructive Pulmonary Disease in 100 participants. Status unknown.

Timeline

1 June 2021

Primary endpoint
10 August 2022

31 December 2023

Quick facts

Lead sponsor	University of Zurich
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	100
Start date	1 June 2021
Primary completion	10 August 2022
Estimated completion	31 December 2023
Sites	1 location across Kyrgyzstan

Drugs / interventions tested

Acetazolamide (ACETAZOLAMIDE) — full drug profile →
Placebo

Conditions studied

Chronic Obstructive Pulmonary Disease — all drugs for Chronic Obstructive Pulmonary Disease →
Altitude Sickness — all drugs for Altitude Sickness →
Altitude Hypoxia — all drugs for Altitude Hypoxia →

Sponsor

University of Zurich

Who can join

Adults 35 to 75, any sex, with Chronic Obstructive Pulmonary Disease or Altitude Sickness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this randomized, placebo-controlled double-blind trial is to evaluate efficacy of acetazolamide in preventing overt altitude-related adverse health effects (ARAHE) in lowlanders with chronic obstructive pulmonary disease (COPD) developing early signs of altitude-illness during altitude travel.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Validation of Noninvasive Assessment of Pulmonary Gas Exchange in Patients with Chronic Obstructive Pulmonary Disease during Initial Exposure to High Altitude.
Champigneulle B, Reinhard L, Mademilov M, Marillier M, et al · · 2023 · cited 2× · PMID 36769447 · DOI 10.3390/jcm12030795
Pulmonary haemodynamics by echocardiography over 3 days of acclimatization in lowlanders with chronic obstructive pulmonary disease travelling to 3100 m of high altitude.
Bitos K, Müller J, Omuralieva A, Schneider SR, et al · · 2025 · PMID 40134848 · DOI 10.1093/ehjopen/oeaf017

Verify or expand the search:

Other trials of Acetazolamide

Trials testing the same drug.

NCT07372040 — Add-on Diuretics in Acute Decompensated Heart Failure · Phase 2 · recruiting
NCT06945848 — Venous Stenting Evaluation in Patients With Intracranial Hypertension Under Long-term Acetazolamide · NA · recruiting
NCT07199088 — Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Ac · NA · recruiting
NCT03806751 — A Noninvasive Arterial Input Estimation Method for O-15 PET and Integrated PET/MR Scanning · EARLY_PHASE1 · withdrawn
NCT06166654 — Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload · Phase 4 · recruiting

Other recruiting trials for Chronic Obstructive Pulmonary Disease

Currently open trials in the same condition.

NCT06749262 — Inclined Versus Standard Exercise for COPD Patients · NA · recruiting
NCT07406659 — Different Inspiratory Muscle Trainings in Patients With COPD · NA · recruiting
NCT07051707 — Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD · NA · recruiting
NCT07418736 — A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease · Phase 2 · recruiting
NCT07069829 — Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo · recruiting

Other University of Zurich trials

Trials by the same sponsor.

NCT07485699 — Soy Processing and Food Allergy · NA · not yet recruiting
NCT07516912 — Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland · not yet recruiting
NCT07473115 — Individualized Analgesia in the Intensive Care Unit With a New Pain Assessment Bundle and Protocolized Analgesia Adjustm · not yet recruiting
NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
NCT06481982 — Value of Advanced MRI Techniques in the Assessment of Endometriosis · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04913389 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Zurich
Last refreshed: 3 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04913389.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing